PhII ICb With/Without Erbitux in MBC Pts
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- US Oncology Research
- Study ID
- NCT00248287
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Irinotecan + Carboplatin — DRUGirinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
- irinotecan + Carboplatin + erbitux — DRUGirinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
Study Details
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
Key Dates
- Start date
- Jul 28, 2005
- Status verified
- Jan 2025
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 154 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Arm 1irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle (Arm 1, ICb)
- Experimental: Arm 2irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2 Week 1 and then 250 mg/m2 weekly thereafter, (Arm 2, ICb+Erbitux)
Primary Outcome Measure
Objective Response Rates (ORR) [ Time Frame: 2 years ]
Locations (59)
Find similar trials in Birmingham, AL
By condition
By specialty
By research site
Birmingham Hematology and Oncology· Birmingham, ALHematology Oncology Asscociates· Phoenix, AZNorthern AZ Hematology & Oncology Assoc· Sedona, AZRocky Mountain Cancer Center-Rose· Denver, CONorthwestern Connecticut Oncology Hematology Associates· Torrington, CTMelbourne Internal Medicine Associates· Melbourne, FL
Related Studies
- Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal MetastasisPHASE2 · Recruiting · Wake Forest University Health Sciences · Baltimore, Maryland
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPHASE1/PHASE2 · Recruiting · Hoffmann-La Roche · Duarte, California
- Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer PatientsPHASE1/PHASE2 · Recruiting · Weill Medical College of Cornell University · New York, New York
- Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of DiseasePHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · San Carlos, California